Skip to content
FIND A HEALTH VALLEY ACTOR

Dexter®, the Swiss surgery robot, makes its way to Germany

Dexter Distalmotion

The Dexter® on-demand robotic surgery system created by the swiss company Distalmotion is now used by the Department for Women’s Health and Gynecology at the University Hospital Tübingen in Germany.   Prof. Dr. med. Diethelm Wallwiener, Prof. Dr. med. Sara Brucker, Prof. Dr. med. Bernhard Krämer and their teams used theDexter robot in several surgical…

Read More

Debiopharm signs an new IDEAL agreement with the University of Geneva

Debiopharm Unige

Debiopharms and UNIGE want to fight together against cancer and drug-resistant bacterial infections JULY 25, 2022   Debiopharm, a Swiss biopharmaceutical company based in Lausanne, signed of a new agreement as part of its IDEAL (Innovation Debiopharm Academia Léman) initiative with the University of Geneva (UNIGE). The UNIGE Faculty of Medicine has become a partner of the IDEAL program…

Read More

Using proteins as barcodes to fight against counterfeiting

Nano Decoder

Nanodecoder, an EPFL spin-off, receives CHF 100 000 from FIT   The Fondation pour l’Innovation Technologique selection committee announced they have made an Innogrant award of CHF 100 000 to NanoDecoder – an EPFL-based project developing nanopore sensing technologies to fight conterfeiting and perform molecular diagnostics. The startup is working on engineered bio-nanopore providing fast…

Read More

Nestlé Health Science invests EUR 40 million in Enterome

Nestlé - Enterome

Nestlé Health Science has signed a collaboration agreement with French company Enterome to target food allergies and chronic intestinal diseases   Enterome develops new treatments for cancer and autoimmune diseases based on its unique knowledge of the microbiota. With Nestlé Health Science, the french company intends to work on the development of an experimental treatment,…

Read More

Nestlé Health Science and Perseo Pharma partners to fight digestive diseases

Nestlé & Perseo Pharma

Strategic collaboration to create therapies against digestive diseases   Perseo pharma, a preclinical stage biopharmaceutical company focused on breaking new ground in enzyme therapies, has entered a strategic research and development collaboration with Nestlé Health Science S.A. to develop up to three programs targeting enzyme deficiencies in patients suffering from digestive diseases. “We are incredibly…

Read More

ADC Therapeutics signs multi-million dollar licensing agreement with Sobi

ADC Therapeutics

The swiss and the Swedish companies partner for the development and commercialization of ZYNLONTA®, a drug for hematologic and solid tumors   ADC Therapeutics SA has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the…

Read More

Gnubiotics gets a CHF 1.4 million Innosuisse Grant

Gnubiotics

The biotech company evaluates the effects of glycopeptides on solid tumors   Gnubiotics Sciences, a biotech company pioneering the discovery and development of immunomodulatory glycopeptides based in Biopôle, announced that the Swiss Innovation Agency (Innosuisse) will support a research collaboration with the University Hospital Zürich to accelerate the development of Gnubiotics’ GLAAD technology in a…

Read More

CHF 4 million for b-rayZ AG, a startup fighting breast cancer

b-ray Z

The Tech4Eva alumni and University Hospital Zurich (USZ) uses AI for faster and better breast cancer diagnostics     b-RayZ AG has closed an oversubscribed Series A financing round worth over four million Swiss francs with leading investors in the Life Sciences and IT sector. The financing round was led by LifeCare Partners, Protagon AG and…

Read More

KBI Biopharma SA and Selexis SA inaugurated a new facility in Geneva

Selexis - kbi

KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, have inaugurated an expanded, fully-integrated mammalian contract development and manufacturing services facility in Plan-les-Ouates in Geneva, Switzerland. The ~8 700 m2 integrated KBI/Selexis state-of-the-art facility builds upon the companies’ existing market foothold by combining best-in-class cell line development (CLD) and expert mammalian cell…

Read More

Scaling Up Sales

scaling up sales

From the idea to the market, grow your business with a marketing and sales programme   Scaling Up Sales is a program supported by the Service de la promotion de l’économie et de l’innovation (SPEI) of the Canton of Vaud, in partnership with Innovaud and the Fondation pour l’Innovation Technologique (FIT). This program supports SMEs…

Read More